Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer

被引：0
|
作者：
Dan Lu
Chunze Li
Matthew Riggs
Daniel Polhamus
Jonathan French
Priya Agarwal
Shang-Chiung Chen
Shweta Vadhavkar
Monika Patre
Alexander Strasak
Angelica Quartino
Jin Yan Jin
Sandhya Girish
机构：
[1] Genentech,Department of Clinical Pharmacology
[2] Inc.,undefined
[3] Metrum Research Group,undefined
[4] F. Hoffmann-La Roche Ltd.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Trastuzumab emtansine (T-DM1); HER2; Pharmacokinetics; Previously untreated metastatic breast cancer; MARIANNE;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：175 / 185
页数：10
相关论文
共 50 条
  • [41] Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
    Sadeghi, Saeed
    Olevsky, Olga
    Hurvitz, Sara A.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 329 - 338
  • [42] Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
    Recondo, Gonzalo, Jr.
    de la Vega, Maximo
    Galanternik, Fernando
    Diaz-Canton, Enrique
    Amadeo Leone, Bernardo
    Leone, Jose Pablo
    CANCER MANAGEMENT AND RESEARCH, 2016, 8 : 57 - 65
  • [43] Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
    Luai S. Al Rabadi
    Madeline M. Cook
    Andy J. Kaempf
    Megan M. Saraceni
    Michael A. Savin
    Zahi I. Mitri
    BMC Cancer, 21
  • [44] Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer
    De Mattos-Arruda, Leticia
    Cortes, Javier
    ADVANCES IN THERAPY, 2013, 30 (07) : 645 - 658
  • [45] Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer
    Leticia De Mattos-Arruda
    Javier Cortes
    Advances in Therapy, 2013, 30 : 645 - 658
  • [46] Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
    Chunze Li
    Bei Wang
    Shang-Chiung Chen
    Russell Wada
    Dan Lu
    Xin Wang
    Daniel Polhamus
    Jonathan French
    Shweta Vadhavkar
    Alexander Strasak
    Melanie Smitt
    Amita Joshi
    Meghna Samant
    Angelica Quartino
    Jin Jin
    Sandhya Girish
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1079 - 1090
  • [47] Exposure-Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast Cancer
    Wang, J.
    Song, P.
    Schrieber, S.
    Liu, Q.
    Xu, Q.
    Blumenthal, G.
    Kordestani, L. Amiri
    Cortazar, P.
    Ibrahim, A.
    Justice, R.
    Wang, Y.
    Tang, S.
    Booth, B.
    Mehrotra, N.
    Rahman, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (05) : 558 - 564
  • [48] Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
    Diessner, J.
    Bruttel, V.
    Stein, R. G.
    Horn, E.
    Haeusler, S. F. M.
    Dietl, J.
    Hoenig, A.
    Wischhusen, J.
    CELL DEATH & DISEASE, 2014, 5 : e1149 - e1149
  • [49] Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer
    Ring, Alistair
    Wheatley, Duncan
    Hatcher, Helen
    Laing, Robert
    Plummer, Ruth
    Uttenreuther-Fischer, Martina
    Temple, Graham
    Pelling, Katy
    Schnell, David
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2737 - 2744
  • [50] Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
    J Diessner
    V Bruttel
    R G Stein
    E Horn
    S F M Häusler
    J Dietl
    A Hönig
    J Wischhusen
    Cell Death & Disease, 2014, 5 : e1149 - e1149
12345